The end of an era?
Executive Summary
Barr launches generic fluoxetine 20 mg capsule Aug. 2 at $2.67 average wholesale price per capsule, a 10% discount to Lilly's Prozac. The launch follows entry of a final mandate in Prozac patent litigation in Indianapolis district court on July 27. Barr, Par and Geneva will have 180 days of Waxman/Hatch exclusivity on different fluoxetine formulations. Geneva's 10 mg capsule will have an AWP of $2.60; Par's fluoxetine formulations will launch with AWPs per pill of $2.60 (10 mg tablet), $2.67 (20 mg tablet) and $5.34 (40 mg capsule). Lilly's Prozac has a 24.3% share of the serotonin reuptake inhibitor market as of Aug. 3, according to data on the ArcLight "Rxeal Time" database. GSK's Paxil and Pfizer's Zoloft have a 27.2% and 30.0% share of this market, respectively
You may also be interested in...
Barr Expects Metformin Launch By Early February; Pediatric Bill Signed
Barr plans to launch its generic version of Bristol-Myers Squibb's Glucophage (metformin) by early February, CEO Bruce Downey said Jan. 10
Barr Expects Metformin Launch By Early February; Pediatric Bill Signed
Barr plans to launch its generic version of Bristol-Myers Squibb's Glucophage (metformin) by early February, CEO Bruce Downey said Jan. 10
Par Fluoxetine 20 Mg Tabs Have 18% Share Of New Prescriptions
Par's 20 mg tablet formulation of fluoxetine holds an 18% share of new prescriptions for the most common strength of Lilly's Prozac.